Beta Bionics to present at three investor conferences; webcasts available on their website for future replay.
Quiver AI Summary
Beta Bionics, Inc. announced that it will participate in three upcoming investor conferences in September 2025, including the Wells Fargo Healthcare Conference, the Morgan Stanley Healthcare Conference, and the Baird Global Healthcare Conference. Presentations at the Wells Fargo and Morgan Stanley events will be webcast live and available for future viewing on the company's website. Beta Bionics focuses on developing innovative diabetes management solutions, notably the iLet Bionic Pancreas, which is the first FDA-cleared device that automatically calculates insulin doses to enhance treatment outcomes for people with diabetes. For more information, interested parties can visit the Beta Bionics website.
Potential Positives
- Management's participation in multiple investor conferences enhances visibility and engagement with potential investors, showcasing the company's commitment to transparency and growth.
- The live webcasts of the presentations provide an opportunity for broader audience engagement, allowing more investors to connect with the company's strategic vision and developments.
- Beta Bionics' position as a pioneering leader in diabetes management solutions is reinforced by its focus on innovative technologies like the iLet Bionic Pancreas, potentially attracting increased interest from investors in the healthcare sector.
- The FDA-cleared status of the iLet Bionic Pancreas highlights the company's achievement in regulatory approvals, which is crucial for gaining investor confidence and market traction.
Potential Negatives
- Management's engagement in multiple investor conferences may highlight a need for increased capital or investor confidence, indicating potential financial instability.
- The announcement does not include any recent product development or positive financial metrics, which could suggest a lack of significant progress or newsworthy updates from the company.
- By focusing on upcoming events, the press release may imply an absence of current achievements or developments, raising concerns about the company's recent performance or innovations.
FAQ
When will Beta Bionics present at investor conferences?
Beta Bionics will present at the Wells Fargo Conference on September 4, Morgan Stanley Conference on September 8, and Baird Conference on September 10, 2025.
Where can I watch the webcasts of the presentations?
The webcasts will be available on Beta Bionics' website in the "Investors—Events & Presentations" section for live viewing and future replay.
What is the iLet Bionic Pancreas?
The iLet Bionic Pancreas is an FDA-cleared insulin delivery device that autonomously determines insulin doses for diabetes management.
Who can I contact for investor relations at Beta Bionics?
For investor relations inquiries, you can contact Blake Beber at [email protected].
What is the mission of Beta Bionics?
Beta Bionics aims to improve the health and quality of life for insulin-requiring diabetes patients through innovative medical device solutions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BBNX Insider Trading Activity
$BBNX insiders have traded $BBNX stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $BBNX stock by insiders over the last 6 months:
- MARK HOPMAN (Chief Commercial Officer) has made 0 purchases and 4 sales selling 17,026 shares for an estimated $283,905.
- STEPHEN FEIDER (Chief Financial Officer) has made 0 purchases and 4 sales selling 7,084 shares for an estimated $121,954.
- SEAN SAINT (President & CEO) has made 0 purchases and 3 sales selling 3,439 shares for an estimated $61,525.
- MIKE MENSINGER (Chief Product Officer) has made 0 purchases and 3 sales selling 1,115 shares for an estimated $19,947.
- STEVEN JON RUSSELL (Chief Medical Officer) has made 0 purchases and 3 sales selling 1,039 shares for an estimated $18,588.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BBNX Analyst Ratings
Wall Street analysts have issued reports on $BBNX in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 07/30/2025
- Lake Street issued a "Buy" rating on 06/12/2025
- Wolfe Research issued a "Outperform" rating on 05/30/2025
- Stifel issued a "Buy" rating on 02/24/2025
- Piper Sandler issued a "Overweight" rating on 02/24/2025
- Leerink Partners issued a "Outperform" rating on 02/24/2025
To track analyst ratings and price targets for $BBNX, check out Quiver Quantitative's $BBNX forecast page.
$BBNX Price Targets
Multiple analysts have issued price targets for $BBNX recently. We have seen 9 analysts offer price targets for $BBNX in the last 6 months, with a median target of $25.0.
Here are some recent targets:
- Jeff Johnson from Baird set a target price of $17.0 on 07/30/2025
- Richard Newitter from Truist Securities set a target price of $21.0 on 07/30/2025
- Frank Takkinen from Lake Street set a target price of $30.0 on 06/12/2025
- David Roman from Goldman Sachs set a target price of $16.0 on 05/30/2025
- Mike Polark from Wolfe Research set a target price of $20.0 on 05/30/2025
- Mathew Blackman from Stifel set a target price of $25.0 on 02/24/2025
- Matt O'Brien from Piper Sandler set a target price of $26.0 on 02/24/2025
Full Release
IRVINE, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at three upcoming investor conferences (all Eastern Time):
- Wells Fargo 20 th Annual Healthcare Conference on Thursday, September 4, 2025 at 3:45pm
- Morgan Stanley 23 rd Annual Global Healthcare Conference on Monday, September 8, 2025 at 1:50pm
-
Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025 at 9:40am
The presentations at the Wells Fargo and Morgan Stanley conferences will be webcast live. The link to the webcasts will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com , and will be archived there for future replay following the events.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com .
Investor Relations:
Blake Beber
Head of Investor Relations
[email protected]
Media and Public Relations
:
Karen Hynes
Vice President of Marketing
[email protected]
Source: Beta Bionics, Inc.
